Credit: Ludwig Cancer Research
MAY 24, 2021, NEW YORK - A Ludwig Cancer Research study has discovered how to revive a powerful but functionally inert subset of anti-cancer immune cells that are often found within tumors for cancer therapy.
Led by Ludwig Lausanne s Ping-Chih Ho and Li Tang of the École Polytechnique Fédérale de Lausanne, the study describes how an immune factor known as interleukin-10 orchestrates the functional revival of terminally exhausted tumor-infiltrating T lymphocytes (TILs), which have so far proved impervious to stimulation by immunotherapies. It also demonstrates that the factor, when applied in combination with cell therapies, can eliminate tumors in mouse models of melanoma and colon cancer. The findings are reported in the current issue of
MAY 24, 2021, NEW YORK - A Ludwig Cancer Research study has discovered how to revive a powerful but functionally inert subset of anti-cancer immune cells.